Profile data is unavailable for this security.
About the company
Laboratorios Farmaceuticos ROVI SA (ROVI) is a Spain-based company principally engaged in the pharmaceutical industry. The Company’s main activities include the development and commercialization, nationwide and abroad, of medicines and drugs. Its products are structured into three fields: Diagnostic, which offers contrast mediums for use in magnetic resonance, ultrasound and X-ray diagnostics; Prescription, which distributes medicines under such brands as Hibor, Osseor, Hepadren, Pneumovax-23, Glufan, Corlentor, Exxiv, Calcio y Vitamina D3 Rovi and Absorcol, among others; and Over The Counter (OTC), which comprises the Perspirex, Enerzona, Dentimelo and ColdPack brands. The Company owns such fully consolidated subsidiaries as Gineladius SL, Frosst Iberica SA, Rovi Contract Manufacturing SL and Bertex Pharma GmbH, among others.
- Revenue in EUR (TTM)799.25m
- Net income in EUR165.00m
- Incorporated1946
- Employees2.14k
- LocationLaboratorios Farmaceuticos ROVI SAC/ Julian Camarillo, 35MADRID 28037SpainESP
- Phone+34 913756230
- Fax+34 913047881
- Websitehttps://www.rovi.es/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tianjin Pharmcetl Da Ren Tang Grp Cp Ltd | 1.06bn | 122.99m | 2.96bn | 4.62k | 27.86 | 4.03 | -- | 2.79 | 1.21 | 1.21 | 10.42 | 8.34 | 0.7567 | 2.64 | 3.24 | 1,740,681.00 | 8.66 | 8.96 | 13.55 | 12.80 | 45.80 | 40.82 | 11.44 | 10.67 | 1.31 | -- | 0.2047 | 56.93 | -0.3266 | 5.28 | 14.49 | 11.93 | -4.33 | 42.22 |
| Tasly Pharmaceutical Group Co Ltd | 1.13bn | 116.19m | 2.96bn | 9.22k | 25.59 | 1.77 | -- | 2.62 | 0.5878 | 0.5878 | 5.73 | 8.51 | 0.4964 | 1.73 | 8.48 | 928,676.30 | 4.89 | 5.47 | 6.14 | 7.25 | 65.28 | 48.42 | 9.86 | 8.94 | 2.19 | 3.89 | 0.1766 | 50.99 | 0.4236 | -13.57 | 505.34 | -7.07 | -3.03 | 1.92 |
| Laurus Labs Ltd | 570.92m | 14.81m | 2.98bn | 6.01k | 201.06 | 6.38 | 48.37 | 5.22 | 2.43 | 2.43 | 93.70 | 76.70 | 0.602 | 1.18 | 3.06 | 8,412,186.00 | 1.55 | 10.13 | 2.52 | 16.47 | 53.44 | 47.63 | 2.58 | 12.83 | 0.5818 | 1.81 | 0.4023 | 13.00 | -16.55 | 17.07 | -79.68 | 11.36 | 21.68 | 21.67 |
| HUTCHMED (China) Ltd | 583.19m | -40.07m | 2.98bn | 1.97k | -- | 4.22 | -- | 5.11 | -0.3887 | -0.3887 | 5.51 | 6.61 | 0.4775 | 7.10 | 4.15 | 2,391,453.00 | -3.30 | -14.35 | -4.65 | -20.43 | 41.67 | 36.57 | -6.91 | -31.44 | 2.68 | -- | 0.0984 | -- | 96.52 | 31.38 | 127.93 | -- | 38.65 | -- |
| J B Chemicals and Pharmaceuticals Ltd | 419.31m | 69.05m | 2.99bn | 5.31k | 44.27 | 8.23 | 34.40 | 7.12 | 38.45 | 38.45 | 233.33 | 206.82 | 0.9481 | 2.59 | 4.85 | 6,987,882.00 | 15.61 | 15.77 | 18.62 | 18.89 | 66.26 | 61.18 | 16.47 | 16.06 | 2.20 | 27.53 | 0.0303 | 33.08 | 10.63 | 16.22 | 34.84 | 23.36 | 40.15 | 37.42 |
| China Resources Dubl-Crne Phrmctl Co Ltd | 1.48bn | 217.96m | 3.03bn | 12.27k | 13.74 | 2.25 | -- | 2.04 | 1.61 | 1.61 | 10.93 | 9.81 | 0.7106 | 3.04 | 6.08 | 914,865.00 | 10.54 | 8.40 | 14.70 | 11.08 | 56.34 | 58.19 | 14.83 | 11.98 | 1.26 | -- | 0.0633 | 35.91 | 6.20 | 4.44 | 12.96 | 6.60 | 21.46 | -1.63 |
| Nanjing King-Frind Bchmcl Phrmctcl C Ltd | 511.48m | -55.79m | 3.05bn | 1.45k | -- | 3.69 | -- | 5.97 | -0.3269 | -0.3269 | 2.43 | 3.88 | 0.3774 | 0.5012 | 4.35 | 2,672,280.00 | -4.12 | 8.97 | -5.76 | 13.15 | 41.00 | 45.59 | -10.91 | 20.12 | 1.51 | -2.96 | 0.269 | 26.33 | 5.89 | 18.25 | -117.37 | -- | 38.32 | 13.75 |
| PTC Therapeutics, Inc. | 859.86m | -432.67m | 3.16bn | 988.00 | -- | -- | -- | 3.67 | -5.94 | -5.94 | 11.79 | -13.70 | 0.5807 | 1.97 | 4.93 | 911,603.30 | -29.22 | -26.71 | -45.34 | -33.46 | 92.20 | 93.94 | -50.32 | -83.80 | 2.04 | -0.7925 | 1.79 | -- | 34.20 | 28.78 | -12.09 | -- | 32.00 | -- |
| Laboratorios Farmaceuticos ROVI SA | 799.25m | 165.00m | 3.17bn | 2.14k | 19.47 | 5.84 | 16.64 | 3.96 | 3.18 | 3.18 | 15.41 | 10.59 | 0.9356 | 0.8462 | 4.94 | 378,611.10 | 19.31 | 18.90 | 26.32 | 25.58 | 62.29 | 59.82 | 20.64 | 20.13 | 0.9353 | 150.71 | 0.1869 | 34.37 | 1.44 | 22.30 | -14.69 | 56.93 | 15.84 | 69.11 |
| Apellis Pharmaceuticals Inc | 682.82m | -238.77m | 3.30bn | 702.00 | -- | 14.29 | -- | 4.83 | -2.04 | -2.04 | 5.81 | 1.94 | 0.8316 | 0.8814 | 3.19 | 1,018,828.00 | -29.08 | -73.88 | -37.24 | -90.03 | 86.47 | -- | -34.97 | -326.49 | 3.73 | -9.20 | 0.656 | -- | 425.83 | -- | 18.94 | -- | -- | -- |
| Gland Pharma Ltd | 665.48m | 78.14m | 3.33bn | 4.22k | 42.57 | 3.35 | 27.38 | 5.00 | 41.98 | 41.98 | 357.57 | 533.41 | 0.5567 | 1.28 | 4.11 | 13,967,630.00 | 6.54 | 13.23 | 7.65 | 14.56 | 60.30 | 55.58 | 11.74 | 22.92 | 3.14 | 33.11 | 0.0358 | 7.26 | 56.29 | 22.61 | -1.10 | 11.32 | 24.02 | -- |
Data as of Nov 21 2024. Currency figures normalised to Laboratorios Farmaceuticos ROVI SA's reporting currency: Euro EUR
10.45%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (World Investors)as of 30 Sep 2024 | 1.16m | 2.26% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 743.23k | 1.45% |
| T. Rowe Price International Ltd.as of 30 Sep 2024 | 708.09k | 1.38% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 502.30k | 0.98% |
| Invesco Asset Management Ltd.as of 30 Sep 2024 | 454.45k | 0.89% |
| Santander Private Banking Gestion SA SGIICas of 30 Jun 2024 | 402.18k | 0.79% |
| Dimensional Fund Advisors LPas of 07 Nov 2024 | 383.20k | 0.75% |
| BNP Paribas Asset Management Europe SASas of 31 Oct 2024 | 364.66k | 0.71% |
| RBC Global Asset Management (UK) Ltd.as of 30 Sep 2024 | 360.38k | 0.70% |
| ProfitlichSchmidlin AGas of 30 Aug 2024 | 280.51k | 0.55% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
